Site-specific characterization of N- and O-linked glycosylation in prostate cancer tissues as molecular signature for disease progression

• Grant number: 17/03010-8
• Support type: Scholarships abroad - Research Internship - Post-doctor
• Effective date (Start): July 10, 2017
• Effective date (End): July 09, 2018
• Field of knowledge: Biological Sciences - Biochemistry - Chemistry of Macromolecules
• Principal researcher: Giuseppe Palmisano
• Grantee: Rebeca Kawahara Sakuma
• Supervisor abroad: Morten Thaysen Andersen
• Home Institution: Instituto de Ciências Biomédicas (ICB). Universidade de São Paulo (USP). São Paulo , SP, Brazil
• Research place: Macquarie University, Australia
• Associated to the scholarship: 15/02866-0 - DISCOVERY AND VERIFICATION OF INTACT GLYCOPEPTIDES AS CANDIDATE PROSTATE CANCER BIOMARKERS USING MASS SPECTROMETRY-BASED PROTEOMICS APPROACHES, BP.PD

Abstract

Prostate cancer (PCa) is the second most common cancer in men worldwide. Gleason score classification is the most important predictor of PCa outcomes and is influential in determining patient treatment options. However, tumor heterogeneity, biopsy-sampling error, and variations in biopsy interpretation are still key challenges for accurate prognostication, leading to significant overtreatment, with associated costs and morbidity. Changings in the glycosylation profile as well as in the glycosylation enzymes were previously described to be associated with prostate cancer detection and aggressiveness and we showed that differentially regulated glycopeptides are able to discriminate urines from prostate cancer and benign conditions (ongoing regular FAPESP project, 2015/02866-0). However, no systematic correlation between altered glycosylation pattern and site-specific changes in protein glycosylation in prostate cancer tissues as prognostic predictor was reported. Therefore, following on the previous work on urine glycoproteins, the objective of this project is to associate site-specific N- and O-linked glycosylation changes with Gleason Score classification, as a strategy to discriminate indolent tumor vs aggressive tumor. For that, quantitative mass spectrometry-based glycoproteomics and glycomics strategies will be performed in human fresh tissues, which will be grouped according to low gleason score (d6), intermediate (7) and high (8-10). Specific glycosylation changes that can potentially discriminate the different Gleason Score groups will be evaluated in larger cohort samples using complementary quantitative strategies. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

KAWAHARA, REBECA; RECUERO, SAULO; SROUGI, MIGUEL; LEITE, KATIA R. M.; THAYSEN-ANDERSEN, MORTEN; PALMISANO, GIUSEPPE. The Complexity and Dynamics of the Tissue Glycoproteome Associated With Prostate Cancer Progression. MOLECULAR & CELLULAR PROTEOMICS, v. 20, 2021. Web of Science Citations: 3.

CHATTERJEE, SAYANTANI; LEE, LING Y.; KAWAHARA, REBECA; ABRAHAMS, JODIE L.; ADAMCZYK, BARBARA; ANUGRAHAM, MERRINA; ASHWOOD, CHRISTOPHER; SUMER-BAYRAKTAR, ZEYNEP; BRIGGS, MATTHEW T.; CHIK, JENNY H. L.; EVEREST-DASS, ARUN; FOERSTER, SARAH; HINNEBURG, HANNES; LEITE, KATIA R. M.; LOKE, IAN; MOGINGER, UWE; MOH, EDWARD S. X.; NAKANO, MIYAKO; RECUERO, SAULO; SETHI, MANVEEN K.; SROUGI, MIGUEL; STAVENHAGEN, KATHRIN; VENKATAKRISHNAN, VIGNESH; WONGTRAKUL-KISH, KATHERINE; DIESTEL, SIMONE; HOFFMANN, PETER; KARLSSON, NICLAS G.; KOLARICH, DANIEL; MOLLOY, MARK P.; MUDERS, MICHAEL H.; OEHLER, MARTIN K.; PACKER, NICOLLE H.; PALMISANO, GIUSEPPE; THAYSEN-ANDERSEN, MORTEN. Protein Paucimannosylation Is an Enriched N-Glycosylation Signature of Human Cancers. PROTEOMICS, v. 19, n. 21-22, SI NOV 2019. Web of Science Citations: 2.

KAWAHARA, REBECA; RECUERO, SAULO; NOGUEIRA, FABIO C. S.; DOMONT, GILBERTO B.; LEITE, KATIA R. M.; SROUGI, MIGUEL; THAYSEN-ANDERSEN, MORTEN; PALMISANO, GIUSEPPE. Tissue Proteome Signatures Associated with Five Grades of Prostate Cancer and Benign Prostatic Hyperplasia. PROTEOMICS, v. 19, n. 21-22, SI NOV 2019. Web of Science Citations: 0.